Drug Addiction

• General Topics.- DARPP-32 Mediates the Actions of Multiple Drugs of Abuse.- Drug Discovery From Natural Sources.- Computational Methods in Drug Design: Modeling G Protein-Coupled Receptor Monomers, Dimers, and Oligomers.- Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse.- Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse.- Cocaine- and Amphetamine-Regulated Transcript Peptides Play a Role in Drug Abuse and Are Potential Therapeutic Targets.- RNAi-Directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy.- Viewing Chemokines as a Third Major System of Communication in the Brain.- Targeting the PDZ Domains of Molecular Scaffolds of Transmembrane Ion Channels.- Neuronal Nicotinic Acetylcholine Receptor Expression and Function on Nonneuronal Cells.- Transporters & Stimulants & Hallucinogens.- Role of Monoamine Transporters in Mediating Psychostimulant Effects.- Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse.- Serotonin Transporters: Implications for Antidepressant Drug Development.- Recent Advances for the Treatment of Cocaine Abuse: Central Nervous System Immunopharmacotherapy.- ? Opioids as Potential Treatments for Stimulant Dependence.- Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants.- Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors.- Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters.- Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions.- Receptors of Mammalian TraceAmines.- Drug Design: Nicotine, Opioids and Related Ligands.- The Role of Crystallography in Drug Design.- Opioid Peptide-Derived Analgesics.- Opioid Ligands with Mixed ?/? Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics.- Small-Molecule Agonists and Antagonists of the Opioid Receptor-Like Receptor (ORL1, NOP): Ligand-Based Analysis of Structural Factors Influencing Intrinsic Activity at NOP.- Kappa Opioid Antagonists: Past Successes and Future Prospects.- In Vitro and Direct In Vivo Testing of Mixture-Based Combinatorial Libraries for the Identification of Highly Active and Specific Opiate Ligands.- Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-Specific Antibodies.- New Paradigms and Tools in Drug Design for Pain and Addiction.- Opioids: General.- Neuropeptide-Processing Enzymes: Applications for Drug Discovery.- CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier.- Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants.- Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development.- Homology Modeling of Opioid Receptor-Ligand Complexes Using Experimental Constraints.- Molecular Recognition of Opioid Receptor Ligands.- Role of Morphine’s Metabolites in Analgesia: Concepts and Controversies.- Mu Opioid Receptor Regulation and Opiate Responsiveness.- Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence.- Cannabinoid.- The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids.- Further Advances in the Synthesis of Endocannabinoid-Related Ligands.- Ajulemic Acid (IP-751): Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials.-Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs.- Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids.- 2-Arachidonoylglycerol (2-AG) Membrane Transport: History and Outlook.- Endocannabinoid Mechanisms of Pain Modulation.

From the reviews:"This book grew out of a symposium entitled ‘Frontiers in Science: Drug Addiction–From Basic Research to Therapies’ held at the end of 2004. … The book is composed of 44 chapters, all concerned with basic science research relevant to drug dependence. … even for basic scientists this book is best approached as one where at most a few chapters may be of interest to any researcher … in drug addiction." (Jason White, Drug And Alcohol Review, Vol. 28, July, 2009)